Takeda Pharmaceutical Initiates Phase II Clinical Test for Compound TAK-491 for Treatment of Hypertension.Tokyo, Japan, July 13, 2006 - (JCN JCN Japan Corporate NewsJCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical has announced that its investigational compound TAK-491 has entered into the Phase II clinical stage in the US and Europe. An angiotensin receptor blocker (ARB) discovered by Takeda, TAK-491 helps lower blood pressure by suppressing the action of vasopressor vasopressor /vaso·pres·sor/ (-pres´er) 1. stimulating contraction of the muscular tissue of the capillaries and arteries. 2. an agent that so acts. va·so·pres·sor adj. hormone Angiotensin II. The new compound is superior to the conventional ARB in that it demonstrates stronger anti-hypertension action, improves the insulin resistance, and decreases proteinuria proteinuria /pro·tein·uria/ (-ur´e-ah) an excess of serum proteins in the urine, as in renal disease or after strenuous exercise.proteinu´ric pro·tein·u·ri·a n. 1. . TAK-491 is expected to support the expansion of the US diabetic franchise of Actos (generic name: pioglitazone HCI (Human Computer Interaction) Refers to the design and implementation of computer systems that people interact with. It includes desktop systems as well as embedded systems in all kinds of devices. ) into lifestyle-related diseases. Also, the new drug will help the company increase its presence in the European cardiovascular market along with Candesartan, another drug found by Takeda which treats hypertension. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion